BlackRock Health Sciences Opportunities Portfolio Institutional Shares
SHSSX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Bellevue Parkway Wilmington DE United States of America 19809
- IPO Date
- Oct 16, 2000
- CIK
- 0000844779
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Opportunities Portfolio Institutional Shares (SHSSX) is an open-end mutual fund managed by BlackRock Advisors, LLC that seeks long-term capital growth by investing at least 80% of its total assets in equity securities, primarily common stocks, of companies in health sciences and related industries; these include health care equipment and supplies, health care providers and services, biotechnology, pharmaceuticals, and life sciences research and development. The fund concentrates more than 25% of its assets in the health sciences sector, with flexibility to invest in non-U.S. companies and a portfolio featuring top holdings such as Eli Lilly and Company (10.88%), Johnson & Johnson (8.36%), Abbott Laboratories (5.02%), AbbVie Inc. (3.96%), and Thermo Fisher Scientific Inc. (3.69%), alongside approximately 90% U.S. stocks, 6-7% non-U.S. stocks, and minimal cash or bonds. Additional exposure spans medical devices, diagnostics, and emerging biotech firms, exemplified by recent portfolio additions like Galderma Group AG, Exelixis Inc., Summit Therapeutics Inc., and Kymera Therapeutics Inc. Operated within BlackRock, Inc., the world's largest asset manager with $12.5 trillion in assets under management as of 2025 and headquartered in New York City, the fund launched on October 16, 2000, and targets institutional investors with a minimum initial investment of $2.0 million, offering share classes including Institutional (SHSSX), Class K (SHSKX), Investor A (SHSAX), Investor C (SHSCX), Service (SHISX), and Class R (BHSRX). BlackRock, founded in 1988, maintains global operations across 70 offices in 30 countries, serving clients in 100 countries, with the fund domiciled in the United States and exhibiting a large-cap blend/growth investment style in the Morningstar Health category. The fund is led by portfolio managers Erin Xie, PhD (Managing Director since 2003) and Xiang Liu, PhD (Managing Director since 2020), who apply fundamental analysis within BlackRock's Active Equity Group. In a recent development, BlackRock completed its acquisition of HPS Investment Partners in June 2025, enhancing its alternatives platform and potentially bolstering research capabilities relevant to health sciences investments, while the fund continues active position adjustments amid sector volatility. As of September 30, 2025, the fund reports total assets of approximately $8.4 billion, a net expense ratio of 0.84%, and annualized returns including 9.49% over 10 years, with performance benchmarked against health sector indices.